Roberto Latini

Title: Innovations by Roberto Latini in Cardiac Diagnostics

Introduction

Roberto Latini is an accomplished inventor based in Milan, Italy. He has made significant contributions to the field of cardiac diagnostics, holding a total of 4 patents. His work focuses on innovative methods for predicting and diagnosing cardiovascular conditions, particularly atrial fibrillation.

Latest Patents

Latini's latest patents include a method for predicting the risk of recurrence of atrial fibrillation based on measuring the biomarker Angiopoietin-2 (Ang-2). This method not only aids in predicting recurrence but also assists in diagnosing atrial fibrillation in subjects suspected of having the condition. Additionally, he has developed a method for assessing whether a subject should undergo imaging-based diagnostic assessments, which involves determining the levels of cardiac Troponin and Fibroblast Growth Factor 23 (FGF-23) in samples. This invention also encompasses methods for predicting mortality risk and diagnosing early stages of left ventricular hypertrophy (LVH).

Career Highlights

Roberto Latini is currently associated with Roche Diagnostics Operations, Inc., where he continues to innovate in the field of medical diagnostics. His expertise and inventions have the potential to significantly improve patient outcomes in cardiovascular health.

Collaborations

Latini has collaborated with notable professionals in his field, including Serge Masson and Dirk Block. These collaborations have further enhanced the impact of his inventions in the medical community.

Conclusion

Roberto Latini's contributions to cardiac diagnostics through his innovative patents demonstrate his commitment to advancing medical technology. His work is poised to make a lasting impact on the diagnosis and treatment of cardiovascular diseases.